company background image
ZLD

Zelira Therapeutics ASX:ZLD Stock Report

Last Price

AU$1.81

Market Cap

AU$17.3m

7D

0.6%

1Y

-75.4%

Updated

16 Aug, 2022

Data

Company Financials +
ZLD fundamental analysis
Snowflake Score
Valuation1/6
Future Growth2/6
Past Performance0/6
Financial Health4/6
Dividends0/6

ZLD Stock Overview

Zelira Therapeutics Limited, a bio-pharmaceutical company, engages in the development of cannabinoid-based medicines for the treatment of various medical conditions in Australia.

Zelira Therapeutics Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Zelira Therapeutics
Historical stock prices
Current Share PriceAU$1.81
52 Week HighAU$8.75
52 Week LowAU$0.90
Beta1.68
1 Month Change-44.99%
3 Month Change31.16%
1 Year Change-75.37%
3 Year Change-85.01%
5 Year Change-87.69%
Change since IPO-55.03%

Recent News & Updates

Jul 14
Is Zelira Therapeutics (ASX:ZLD) In A Good Position To Invest In Growth?

Is Zelira Therapeutics (ASX:ZLD) In A Good Position To Invest In Growth?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Shareholder Returns

ZLDAU PharmaceuticalsAU Market
7D0.6%2.2%0.7%
1Y-75.4%-10.7%-6.5%

Return vs Industry: ZLD underperformed the Australian Pharmaceuticals industry which returned -10.7% over the past year.

Return vs Market: ZLD underperformed the Australian Market which returned -6.5% over the past year.

Price Volatility

Is ZLD's price volatile compared to industry and market?
ZLD volatility
ZLD Average Weekly Movement23.8%
Pharmaceuticals Industry Average Movement12.5%
Market Average Movement10.6%
10% most volatile stocks in AU Market17.9%
10% least volatile stocks in AU Market4.6%

Stable Share Price: ZLD is more volatile than 90% of Australian stocks over the past 3 months, typically moving +/- 24% a week.

Volatility Over Time: ZLD's weekly volatility has increased from 16% to 24% over the past year.

About the Company

FoundedEmployeesCEOWebsite
2003n/aOludare Odumosuhttps://www.zeliratx.com

Zelira Therapeutics Limited, a bio-pharmaceutical company, engages in the development of cannabinoid-based medicines for the treatment of various medical conditions in Australia. The company is also involved in a human clinical trial program focused on insomnia, autism, and opioid reduction; and a pre-clinical research program to examine the effect of cannabinoids in breast, brain, and pancreatic cancer, as well as the potential for cannabinoid formulations to treat diabetes-associated cognitive decline. It offers formulations under the HOPE brand in Pennsylvania and Louisiana, as well as develops Zenivol, a cannabinoid-based medicine for treatment of chronic insomnia.

Zelira Therapeutics Limited Fundamentals Summary

How do Zelira Therapeutics's earnings and revenue compare to its market cap?
ZLD fundamental statistics
Market CapAU$17.33m
Earnings (TTM)-AU$10.22m
Revenue (TTM)AU$1.30m

13.3x

P/S Ratio

-1.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ZLD income statement (TTM)
RevenueAU$1.30m
Cost of RevenueAU$862.50k
Gross ProfitAU$438.02k
Other ExpensesAU$10.66m
Earnings-AU$10.22m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-1.07
Gross Margin33.68%
Net Profit Margin-785.91%
Debt/Equity Ratio0%

How did ZLD perform over the long term?

See historical performance and comparison